A nurse is providing education about insulin management to a client newly diagnosed with type 1 diabetes mellitus. Which of the following statements by the nurse about injection site selection is accurate?

Choice A Reason:

Swollen and enlarged veins, also known as varicose veins, are a common manifestation of peripheral venous disease (PVD). This condition occurs when the valves in the veins become weak or damaged, leading to blood pooling and increased pressure within the veins. This results in the veins becoming enlarged, twisted, and visible under the skin1. Varicose veins can cause discomfort, pain, and a heavy feeling in the legs. They are often exacerbated by prolonged standing or sitting and can be a cosmetic concern as well.

Choice B Reason:

Loss of pigmentation over the shin area is not typically associated with peripheral venous disease. This symptom is more commonly seen in conditions such as chronic venous insufficiency (CVI), where prolonged venous hypertension leads to skin changes, including hyperpigmentation and lipodermatosclerosis. However, it is not a primary manifestation of PVD itself.

Choice C Reason:

A shiny appearance to the lower extremities is more commonly associated with peripheral arterial disease (PAD) rather than peripheral venous disease. In PAD, reduced blood flow to the extremities can cause the skin to become thin, shiny, and hairless. This is due to the lack of oxygen and nutrients reaching the skin and underlying tissues. In contrast, PVD primarily affects the veins and does not typically cause these skin changes.

Choice D Reason:

Diminished hair growth on the lower extremities is another symptom more commonly associated with peripheral arterial disease (PAD). In PAD, the reduced blood flow to the extremities can lead to hair loss, as the hair follicles do not receive adequate oxygen and nutrients. Peripheral venous disease, on the other hand, does not usually cause hair loss. Instead, it is characterized by symptoms related to venous insufficiency, such as varicose veins, swelling, and skin changes.

Choice A reason:

Serum phosphate levels are not the primary concern in the management of diabetes insipidus (DI). While phosphate levels are important for overall health, they do not directly relate to the condition or its treatment with desmopressin. DI primarily affects water balance and sodium levels in the body.

Choice B reason:

Serum calcium levels, although important, are not the most critical lab value to monitor in a client with DI receiving desmopressin. Calcium levels are crucial for bone health and various metabolic functions, but they do not directly reflect the effectiveness or complications of desmopressin therapy.

Choice C reason:

Serum sodium levels are the most important lab value to monitor in a client with DI receiving desmopressin. DI causes an imbalance in water regulation, leading to excessive urination and potential dehydration. Desmopressin helps to reduce urine output and maintain water balance, but it can also lead to water retention and hyponatremia (low sodium levels). Monitoring serum sodium is crucial to prevent complications such as seizures, confusion, and other neurological symptoms associated with hyponatremia.

Choice D reason:

Blood urea nitrogen (BUN) levels are useful in assessing kidney function and hydration status, but they are not the primary concern in the management of DI with desmopressin. While BUN levels can provide valuable information about renal function, they do not directly indicate the effectiveness or potential complications of desmopressin therapy.